Salarius Pharmaceuticals Inc (SLRX)

[axelvento]

zero dilution$$$$$

This common stock purchase agreement with Aspire Capital provides Salarius with additional access to capital and financing flexibility allowing Salarius to further advance its lead drug candidate, Seclidemstat,” commented David Arthur, Chief Executive Officer of Salarius. “We believe our non-dilutive financial support from both CPRIT and the National Pediatric Cancer Foundation, now combined with funding from Aspire Capital, puts Salarius in a good financial position as we continue our work targeting the epigenetic causes of cancer.”

http://salariuspharma.com/2019/10/28/salarius-pharmaceuticals-and-aspire-capital-announce-a-10-9m-common-stock-purchase-agreement/